Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
about
Update on the treatment of patients with non-genotype 1 hepatitis C virus infectionBest strategies for global HCV eradication.Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strainsMicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patientsNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.Genetic diversity of hepatitis C virus in Ethiopia.Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects.Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rateIn vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysisNew insight into HCV E1/E2 region of genotype 4a.Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.The impact of host factors on management of hepatitis C virus.Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa.The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseSofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from BelgiumRe-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis.Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis.NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patientsPerformance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients.Effects of Nigella sativa on outcome of hepatitis C in Egypt.IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection.SASLT practice guidelines: management of hepatitis C virus infection.A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity.Treatment of non-genotype 1 hepatitis C virus patients.The future for the treatment of genotype 4 chronic hepatitis C.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.Hepatitis C therapy in non-genotype 1 patients: the near future.How to optimize HCV therapy in genotype 4 patients.Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.Optimal therapy in genotype 4 chronic hepatitis C: finally cured?Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report.
P2860
Q27000806-FF279132-6BAB-408E-8209-1970EF10A160Q27693824-4EDA9E23-0376-4C43-8C50-6F049B4BB64AQ28541762-1AB5C9D6-3A69-499B-B31C-5C027061AB3BQ28545051-81A5A46B-64B6-48AD-AD1C-3144C308A051Q33559298-811AC3CF-7A42-473E-B4C5-81D0C361AF9FQ33574642-ACF4ECF8-855A-4A76-95D2-D45EC9861882Q33752089-ADB1647D-2AC9-41DA-9AF1-F6B2F63C33B6Q33826033-7A77EA87-DECB-4BE1-AED0-77C902CC1C74Q33863096-D012D3F4-6BE2-47BD-BC06-03041DF1933AQ33918559-A31CEE8A-DB5D-45FC-B7C6-57537702DF2DQ34008754-5952B31A-F93F-4F0D-B59F-005D71F8BCDEQ34130628-6745D5A5-2EB8-4D95-B109-20450939F10DQ34634693-5FA7DB86-4683-4050-99DA-268CCC9F2437Q34996891-E58FDEF1-B5C2-4E55-98DE-D3CD75AF81A8Q35005196-FD77EBEF-A7A4-4836-B563-F0B59FD6CBB3Q35771879-56E5998A-F770-4A26-9067-FAFC1617C6DBQ35990066-ED687FD8-F659-4F77-BC3C-D084C591A75EQ35995807-59FA6D78-E4B7-454C-B462-9EAF85C7855CQ36218266-C28BCCFF-F6E2-4450-A08D-5F5C2FF5FA06Q36240269-53A1F098-8694-412C-9E1F-37302921146FQ36261373-41865BDA-387D-40A1-9725-EBD93DDDC790Q36294390-A61CCA90-9675-4826-ACEF-E3559BD8E7EAQ36367633-EAC69F45-FD4E-4EAE-BF3D-143B43592409Q36414090-A38D3AE7-9A59-4FF4-A992-EA0A7974F2D9Q36506264-AAD936FE-C4F3-4EA5-941D-67055263DAC6Q36626705-1FD39F59-E4A2-4F13-B8BA-F2E153B85616Q36821645-03C73D7B-30C7-4B86-AD3E-E89B31A46A38Q36963985-ACE0FE7A-4602-472D-9763-00EDDDB8F8ACQ37019765-F6977727-801B-43FB-82B4-0CAC6FF8EAD6Q37640839-D5D847B9-91B1-4580-9E54-688BF741C1A4Q37960400-BC58F3A4-DCB4-4353-9B8C-ADC59B7448F3Q37972775-922BF334-AEF5-45DB-88B9-6BC841BAC9A2Q38002889-6920CE03-BA2E-4F95-ADA7-3B56F5D5F9ACQ38023869-91DB77A5-D567-4C7C-8662-BEA98285730CQ38071388-FC62B92E-7CCA-46B7-B54B-C4D35FE999F5Q38249236-ADAF3273-633A-4D2F-88DF-014278FC0998Q38295814-4A0E072C-E963-4C5D-8954-AC138A723462Q38459012-B91D6AC7-6E41-4B61-9B13-49C07A55B49AQ38771000-811AC8BC-EA80-4B50-B879-5B002D15DCA7Q38861774-33C0BC33-5692-4081-AECD-DE9A1D8CA418
P2860
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of hepatitis C viru ...... an international expert panel.
@en
Management of hepatitis C viru ...... an international expert panel.
@nl
type
label
Management of hepatitis C viru ...... an international expert panel.
@en
Management of hepatitis C viru ...... an international expert panel.
@nl
prefLabel
Management of hepatitis C viru ...... an international expert panel.
@en
Management of hepatitis C viru ...... an international expert panel.
@nl
P2093
P1476
Management of hepatitis C viru ...... an international expert panel
@en
P2093
Ayman A Abdo
Mahmoud A Khattab
Massimo Colombo
Michael P Manns
Mohammed Eslam
Nazir Ibrahim
Peter Ferenci
Piero L Almasio
Samuel S Lee
Stephanos J Hadziyannis
P304
P356
10.1016/J.JHEP.2010.11.016
P577
2010-12-08T00:00:00Z